Devyser launches a new updated NGS assay to simplify thalassemia testing
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed to further simplify genetic testing. The improved technology, will help broader screening for thalassemia with greater precision in detecting structural variants, saving time and ensuring better results for researchers worldwide.
This product will allow laboratories to achieve rapid, comprehensive results, reducing workflow complexity and enabling efficient genetic profiling through a single assay. Devyser Thalassemia v2 offers a streamlined protocol with minimal hands-on time, empowering labs to deliver reliable and reproducible results consistently.
“The Devyser Thalassemia product is one of our most successful products. With thalassemia affecting millions globally, the market for advanced genetic testing is projected to grow significantly. Devyser Thalassemia v2 positions the company as a leader in this expanding field. Our mission with the next generation of this product is to enable more comprehensive, simpler, and more reliable thalassemia testing for clinical researchers worldwide,” said Theis Kipling, CCO at Devyser. “This product embodies our commitment to providing state-of-the-art solutions for genetic research and advancing the field of thalassemia testing.”
Devyser Thalassemia v2 is currently available globally as a Research Use Only (RUO) product. For product details, visit: https://devyser.com/devyser-thalassemia-v2